Keith Kurlander

Hey, fools.

Today, we're zooming out to look at a massive paradigm shift happening in the health sector, one that has profound implication for our culture, our well-being, and the broader economic landscape.

So for decades, traditional mental health systems relied heavily on managing symptoms.

But there's a growing movement backed by serious clinical research and FDA trials pointing toward a totally different model.

It's moving fast.

Just recently, Compass Pathways

which is publicly traded, tickers CMPS, saw its stock jump over 23% after announcing that it's phase three trials for COMP360, the psilocybin treatment, demonstrated a well-tolerated safety profile, and now they're gearing up for the FDA.

So as psychedelic stocks rise on the news, my guests today argue that it's not a hype trade, but rather the kind of the birth of a brand new healthcare category.

So today I have Dr. Will Vanderveer and Keith Kurlander, founders of the Integrative Psychiatry Institute and authors of the new book,

Psychedelic therapy, a revolutionary approach to restoring mental health and recovering your life.

Well, Keith, welcome to the show.

Thanks, good to be here.

Great to be with you.

Let's start right at the foundation.

You know, you argue that the recent surge in stocks like Compass Pathways isn't just a hype trade, but the birth of a brand new healthcare category.

So what belief about psychedelic therapy do most people and most investors get completely wrong?

And why does this misunderstanding matter?

Now, taking a step back, because as we're talking about this, I want to make sure that the viewers and our members understand what exactly is psychedelic therapy?

What is it replacing?

And then what is it doing?